Immuneering | 8-K: Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors -
Immuneering | 8-K: Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors -
Immuneering | 8-K:Immuneering 公布 2024 年第一季度财务业绩并提供最新业务——报告了其 IMM-1-104 针对 RAS 突变实体瘤的 1/2a 期临床试验 1 期的积极业绩-